The European Journal of Health Economics

2002 - 2025

Current editor(s): J.-M.G.v.d. Schulenburg

From:
Springer
Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ)
Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 8, issue 4, 2007

Tobacco policies in the European Union: a need for state and continental harmonisation? pp. 301-304

Fernando Antoñanzas and Roberto Rodríguez

Foreign direct investment in the health care sector and most-favoured locations in developing countries pp. 305-312

J. Outreville

Cost-effectiveness of extended prophylaxis with fondaparinux compared with low molecular weight heparin against venous thromboembolism in patients undergoing hip fracture surgery pp. 313-323

Jonas Lundkvist, David Bergqvist and Bengt Jönsson

The impact of home hospitalization on healthcare costs of exacerbations in COPD patients pp. 325-332

Jaume Puig-Junoy, Alejandro Casas, Jaume Font-Planells, Joan Escarrabill, Carme Hernández, Jordi Alonso, Eva Farrero, Gemma Vilagut and Josep Roca

Pricing matrix model: dealing with uncertainty pp. 333-337

Mark Nuijten

The incidence and cost of cardiac surgery adverse events in Australian (Victorian) hospitals 2003–2004 pp. 339-346

Jonathon Ehsani, Stephen Duckett and Terri Jackson

Assessment of the pharmaceutical market in Poland after accession to the European Union pp. 347-357

Patricia Willert

Costs and quality of life in multiple sclerosis in The Netherlands pp. 359-359

Gisela Kobelt, Jenny Berg, Peter Lindgren, Bert Anten, Mattias Ekman, Peter Jongen, Chris Polman and Bernard Uitdehaag

Volume 8, issue 3, 2007

Editor’s note pp. 179-179

Johann Graf von der Schulenburg and Wolfgang Greiner

Innovation in hospitals: a survey of the literature pp. 181-193

Faridah Djellal and Faïz Gallouj

Risk adjustment policy options for casemix funding: international lessons in financing reform pp. 195-212

Kathryn Antioch, Randall Ellis, Steve Gillett, Daniel Borovnicar and Ric Marshall

Incorporating efficiency in hospital-capacity planning in Germany pp. 213-223

Ludwig Kuntz, Stefan Scholtes and Antonio Vera

Variations in activity and practice patterns: a French study for GPs pp. 225-236

Sophie Béjean, Christine Peyron and Renaud Urbinelli

Income-related health inequality in Belgium: a longitudinal perspective pp. 237-243

Ann Lecluyse

Economic impact of shifting the locus of care for neuropathic pain from specialists to general practitioners pp. 245-251

Ariel Berger, Piotr Kramarz, Gry Kopperud, John Edelsberg and Gerry Oster

Patient access to pharmaceuticals: an international comparison pp. 253-266

Joshua Cohen, Laura Faden, Susan Predaris and Brian Young

Supplier-induced demand: re-examining identification and misspecification in cross-sectional analysis pp. 267-277

Stuart Peacock and Jeffrey Richardson

Is there an association between economic performance and public satisfaction in health care? pp. 279-285

Eddy Adang and George Borm

Why do patients bypass the nearest hospital? An empirical analysis for orthopaedic care and neurosurgery in the Netherlands pp. 287-295

Marco Varkevisser and Stéphanie Geest

Economic aspects of the new Spanish laws on pharmaceutical preparations pp. 297-300

Fernando Antoñanzas, Juan Oliva, Mariola Pinillos and Carmelo Juàrez

Volume 8, issue 2, 2008

Patient access to rheumatoid arthritis treatments pp. 33-34

Bengt Jönsson, Gisela Kobelt and Josef Smolen

Patient access to rheumatoid arthritis treatments pp. 35-38

Bengt Jönsson

The burden of rheumatoid arthritis and access to treatment: a medical overview pp. 39-47

J. Smolen and D. Aletaha

The burden of rheumatoid arthritis and access to treatment: health burden and costs pp. 49-60

J. Lundkvist, F. Kastäng and G. Kobelt

The burden of rheumatoid arthritis and access to treatment: uptake of new therapies pp. 61-86

B. Jönsson, G. Kobelt and J. Smolen

The time for cost-effectiveness in the new European Union member states: the development and role of health economics and technology assessment in the mirror of the Hungarian experience pp. 83-88

László Gulácsi

The burden of rheumatoid arthritis and access to treatment: determinants of access pp. 87-93

J. Lundqvist, F. Kastäng, G. Kobelt and B. Jönsson

Pharmacoeconomic studies in Italy: a critical review of the literature pp. 89-95

D. Cornago, L. Li Bassi, P. Compadri and L. Garattini

The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments pp. 95-106

G. Kobelt and B. Jönsson

The burden of type 2 diabetes in Serbia and the cost-effectiveness of its management pp. 97-103

Vesna Bjegovic, Zorica Terzic, Jelena Marinkovic, Nebojsa Lalic, Sandra Sipetic and Ulrich Laaser

Patients’ willingness to pay for electronic communication with their general practitioner pp. 105-110

Trine Bergmo and Silje Wangberg

Systematic review of economic evaluations and cost analyses of guideline implementation strategies pp. 111-121

Luke Vale, Ruth Thomas, Graeme MacLennan and Jeremy Grimshaw

Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain pp. 123-135

Maureen Rutten- van Mölken, Jan Oostenbrink, Marc Miravitlles and Brigitta Monz

The cost-utility of magnetic resonance imaging for breast cancer in BRCA1 mutation carriers aged 30–49 pp. 137-144

Richard Norman, D. Evans, Douglas Easton and Kenneth Young

Comparative cost-minimisation of oral and intravenous chemotherapy for first-line treatment of non-small cell lung cancer in the UK NHS system pp. 145-151

K. Le Lay, E. Myon, S. Hill, L. Riou-Franca, D. Scott, M. Sidhu, D. Dunlop and R. Launois

An economic analysis of human papillomavirus triage for the management of women with atypical and abnormal Pap smear results in Germany pp. 153-160

Sara Sheriff, K. Petry, Hans Ikenberg, Geoffrey Crouse, Peter Mazonson and Christopher Santas

Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis pp. 161-168

Andrew Palmer, William Valentine, Joshua Ray, Stephane Roze and Noemi Muszbek

Comment on: Should we really worry about “launch delays” of new drugs in OECD countries? by L. Garatinni and S. Ghislandi pp. 169-170

Joshua Cohen

Should we really worry about “launch delays” of new drugs in OECD countries? Reply to J Cohen pp. 171-171

Livio Garattini

Discussion point: should governments buy drug patents? pp. 173-177

Juan Llano

Volume 8, issue 1, 2007

Economic evaluation for pharmaceuticals in Germany pp. 1-2

Bengt Jönsson

Should we really worry about “launch delays” of new drugs in OECD countries? pp. 1-3

Livio Garattini and Simone Ghislandi

Technology assessment in the German context pp. 3-3

Michael Drummond

Cost of breast cancer in Sweden in 2002 pp. 5-15

Mathias Lidgren, Nils Wilking and Bengt Jönsson

Methods for determining cost-benefit ratios for pharmaceuticals in Germany pp. 5-31

Graf v. d. Schulenburg J.-, Christoph Vauth, Thomas Mittendorf and Wolfgang Greiner

Better primary physician services lead to fewer hospital admissions pp. 17-24

Fredrik Carlsen, Jostein Grytten, Julie Kjelvik and Irene Skau

Utility loss and indirect costs following cardiovascular events in hypertensive patients: the ASCOT health economic substudy pp. 25-30

Peter Lindgren, Thomas Kahan, Neil Poulter, Martin Buxton, Patrick Svarvar, Björn Dahlöf and Bengt Jönsson

Risk-adjusted capitation payments: how well do principal inpatient diagnosis-based models work in the German situation? Results from a large data set pp. 31-39

Corinne Behrend, Florian Buchner, Michael Happich, Rolf Holle, Peter Reitmeir and Juergen Wasem

Long-term absenteeism due to sickness in Sweden. How long does it take and what happens after? pp. 41-50

Daniela Andrén

Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany pp. 51-57

B. Brüggenjürgen, P. Lindgren, B. Ehlken, H.-J. Rupprecht and S. Willich

A multilevel analysis on the determinants of regional health care expenditure: a note pp. 59-65

Guillem López-Casasnovas and Marc Saez

Resource use and costs associated with patients treated for depression in primary care pp. 67-76

P. Sobocki, M. Ekman, Hanna Ågren, I. Krakau, B. Runeson, B. Mårtensson and B. Jönsson

A public–private analysis of the new Dutch health insurance system pp. 77-82

Hans Maarse and Yvette Bartholomée